Evidence map›Paper›PMID 25885527›Full record

ArticleOrphanet journal of rare diseases2015

The genotypic and phenotypic spectrum of PIGA deficiency.

Maja Tarailo-Graovac, Graham Sinclair, Sylvia Stockler-Ipsiroglu, Margot Van Allen, Jacob Rozmus, Casper Shyr, Roberta Biancheri, Tracey Oh, Bryan Sayson, Mirafe Lafek and 5 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Orphanet journal of rare diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Promise of gene therapy for congenital neurologic disease due to GPI deficiency.Molecular therapy. Methods & clinical development · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. PIGG variant pathogenicity assessment reveals characteristic features within 19 families.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Maja Tarailo-GraovacCentre for Molecular Medicine and Therapeutics, Vancouver, Canada. maja@cmmt.ubc.ca.
Graham SinclairTreatable Intellectual Disability Endeavour in British Columbia, Vancouver, Canada. gsinclair@cw.bc.ca.
Sylvia Stockler-IpsirogluTreatable Intellectual Disability Endeavour in British Columbia, Vancouver, Canada. sstockler@cw.bc.ca.
Margot Van AllenDepartment of Medical Genetics, University of British Columbia, Vancouver, Canada. mvallen@cw.bc.ca.
Jacob RozmusDivision of Hematology, Oncology & BMT, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada. jrozmus@cw.bc.ca.
Casper ShyrCentre for Molecular Medicine and Therapeutics, Vancouver, Canada. casper@cmmt.ubc.ca.
Roberta BiancheriDepartment of Paediatric Neurology, Children's Hospital Oxford, John Radcliffe Hospital, Oxford, UK. roberta@biancheri.com.
Tracey OhDepartment of Medical Genetics, University of British Columbia, Vancouver, Canada. toh@cw.bc.ca.
Bryan SaysonTreatable Intellectual Disability Endeavour in British Columbia, Vancouver, Canada. Bryan.Sayson@cw.bc.ca.
Mirafe LafekTreatable Intellectual Disability Endeavour in British Columbia, Vancouver, Canada. MLafek@cw.bc.ca.
Colin J RossCentre for Molecular Medicine and Therapeutics, Vancouver, Canada. colinross1@gmail.com.
Wendy P RobinsonDepartment of Medical Genetics, University of British Columbia, Vancouver, Canada. wrobinson@cfri.ca.
Wyeth W WassermanCentre for Molecular Medicine and Therapeutics, Vancouver, Canada. wyeth@cmmt.ubc.ca.
Andrea RossiDepartment of Neuroradiology, Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, I-16147, Genoa, Italy. andrearossi@ospedale-gaslini.ge.it.
Clara D M van KarnebeekCentre for Molecular Medicine and Therapeutics, Vancouver, Canada. cvankarnebeek@cw.bc.ca.
University of British Columbia · CABC Children's Hospital · CAIstituto Giannina Gaslini · ITJohn Radcliffe Hospital · GBPacific Centre for Reproductive Medicine · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhosphatidylinositol glycan biosynthesis class A protein (PIGA) is one of the enzymes involved in the biosynthesis of glycosylphosphatidylinositol (GPI) anchor proteins, which function as enzymes, adhesion molecules, complement regulators and co-receptors in signal transduction pathways. Until recently, only somatic PIGA mutations had been reported in patients with paroxysmal nocturnal hemoglobinuria (PNH), while germline mutations had not been observed, and were suspected to result in lethality. However, in just two years, whole exome sequencing (WES) analyses have identified germline PIGA mutations in male patients with XLIDD (X-linked intellectual developmental disorder) with a wide spectrum of clinical presentations. METHODS AND

resultsHere, we report on a new missense PIGA germline mutation [g.15342986C>T (p.S330N)] identified via WES followed by Sanger sequencing, in a Chinese male infant presenting with developmental arrest, infantile spasms, a pattern of lesion distribution on brain MRI resembling that typical of maple syrup urine disease, contractures, dysmorphism, elevated alkaline phosphatase, mixed hearing loss (a combination of conductive and sensorineural), liver dysfunction, mitochondrial complex I and V deficiency, and therapy-responsive dyslipidemia with confirmed lipoprotein lipase deficiency. X-inactivation studies showed skewing in the clinically unaffected carrier mother, and CD109 surface expression in patient fibroblasts was 57% of that measured in controls; together these data support pathogenicity of this mutation. Furthermore, we review all reported germline PIGA mutations (1 nonsense, 1 frameshift, 1 in-frame deletion, five missense) in 8 unrelated families.

conclusionsOur case further delineates the heterogeneous phenotype of this condition for which we propose the term 'PIGA deficiency'. While the phenotypic spectrum is wide, it could be classified into two types (severe and less severe) with shared hallmarks of infantile spasms with hypsarrhythmia on EEG and profound XLIDD. In severe PIGA deficiency, as described in our patient, patients also present with dysmorphic facial features, multiple CNS abnormalities, such as thin corpus callosum and delayed myelination, as well as hypotonia and elevated alkaline phosphatase along with liver, renal, and cardiac involvement; its course is often fatal. The less severe form of PIGA deficiency does not involve facial dysmorphism and multiple CNS abnormalities; instead, patients present with milder IDD, treatable seizures and generally a longer lifespan.

Indexed as

GenotypeAmino Acid SequenceGerm-Line MutationHumansInfantMaleMembrane ProteinsMolecular Sequence DataMutation, MissenseMembrane Proteinsphosphatidylinositol glycan-class A protein

Identifiers

PMID25885527
PMCPMC4348372
OpenAlexW2104938256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.